T1	Condition 597 616	portal hypertension
T2	Condition-Name 597 616	portal hypertension
E1	Condition:T1 Name:T2
T3	Procedure 34 50	liver transplant
T4	Procedure-Name 34 50	liver transplant
E3	Procedure:T3 Name:T4 Temporality:E2
T5	Procedure 181 197	liver transplant
T6	Procedure-Name 181 197	liver transplant
E5	Procedure:T5 Name:T6
T7	Condition 137 162	polyneuropathy disability
T8	Condition-Name 137 162	polyneuropathy disability
E7	Condition:T7 Name:T8 Polarity:T58
T9	Condition 74 85	amyloidosis
T10	Condition-Name 74 85	amyloidosis
E9	Condition:T9 Name:T10
T11	Procedure 223 248	immunosuppressive regimen
T12	Procedure-Name 223 248	immunosuppressive regimen
E11	Procedure:T11 Name:T12 Stability:T62 Temporality:E18
T13	Condition 622 629	ascites
T14	Condition-Name 622 629	ascites
E13	Condition:T13 Name:T14
T15	Condition 164 167	PND
T16	Condition-Name 164 167	PND
E15	Condition:T15 Name:T16
T17	Condition 797 825	human immunodeficiency virus
T18	Condition-Name 797 825	human immunodeficiency virus
E17	Condition:T17 Name:T18
T19	Procedure 959 976	organ transplants
T20	Procedure-Name 959 976	organ transplants
E19	Procedure:T19 Name:T20 Temporality:E52
T21	Procedure 988 1004	liver transplant
T22	Procedure-Name 988 1004	liver transplant
E21	Procedure:T21 Name:T22
T23	Condition 841 881	New York Heart Association heart failure
T24	Condition-Name 841 881	New York Heart Association heart failure
E23	Condition:T23 Name:T24 Stage:E34
T25	Condition 733 744	amyloidosis
T26	Condition-Name 733 744	amyloidosis
E25	Condition:T25 Name:T26
T27	Condition 769 780	hepatitis B
T28	Condition-Name 769 780	hepatitis B
E27	Condition:T27 Name:T28
T29	Condition 782 793	hepatitis C
T30	Condition-Name 782 793	hepatitis C
E29	Condition:T29 Name:T30
T31	Eq-Operator 86 87	≥
A1	Eq-Operator-Value T31 GTEQ
T32	Eq-Operator 254 255	≤
A2	Eq-Operator-Value T32 LTEQ
T33	Eq-Operator 367 368	≥
A3	Eq-Operator-Value T33 GTEQ
T34	Eq-Operator 397 418	greater than or equal
A4	Eq-Operator-Value T34 GTEQ
T35	Eq-Operator 683 684	≤
A5	Eq-Operator-Value T35 LTEQ
T36	Eq-Operator 900 901	>
A6	Eq-Operator-Value T36 GT
T37	Eq-Temporal-Unit 90 96	months
A7	Eq-Temporal-Unit-Value T37 month
T38	Eq-Temporal-Unit 294 300	months
A8	Eq-Temporal-Unit-Value T38 month
T39	Eq-Value 87 89	12
T40	Eq-Value 255 257	10
T41	Eq-Value 292 293	3
T42	Eq-Value 368 370	70
T43	Eq-Value 684 686	30
T44	Eq-Value 901 902	2
T45	Eq-Comparison 86 96	≥12 months
E30	Eq-Comparison:T45 Operator:T31 Temporal-Unit:T37 Value:T39
T46	Eq-Comparison 254 264	≤10 mg/day
E31	Eq-Comparison:T46 Operator:T32 Value:T40 Unit:T63 Per:T64
T47	Eq-Comparison 367 371	≥70%
E32	Eq-Comparison:T47 Operator:T33 Value:T42 Unit:T78
T48	Eq-Comparison 683 702	≤30 mL/min/1.73 m^2
E33	Eq-Comparison:T48 Operator:T35 Value:T43 Unit:T99 Per:T100 Per2:T101
T49	Eq-Comparison 900 902	>2
E34	Eq-Comparison:T49 Operator:T36 Value:T44
T50	Eq-Comparison 25 33	Received
E2	Eq-Comparison:T50 Temporal-Period:T51
T51	Eq-Temporal-Period 25 33	Received
A9	Eq-Temporal-Period-Value T51 past
T52	Modifier 68 73	hATTR
E4	Modifier:T52 Modifies:T10
T53	Procedure 55 64	treatment
E6	Procedure:T53 Temporality:E30
R1	Using Arg1:E6 Arg2:E3	
R2	Treatment-For Arg1:E6 Arg2:E9	
T54	Study 104 109	study
E8	Study:T54 Temporality:E10
T55	Eq-Comparison 110 115	start
E10	Eq-Comparison:T55 Temporal-Recency:T56
T56	Eq-Temporal-Recency 110 115	start
A10	Eq-Temporal-Recency-Value T56 first-time
T57	Temporal-Connection 97 103	before
E12	Temporal-Connection:T57 Arg:E30 Arg2:E8
A11	Temporal-Connection-Type-Value E12 before
T58	Polarity 125 133	increase
A12	Polarity-Value T58 high
R3	Abbrev-Of Arg1:E15 Arg2:E7	
T59	Temporal-Connection 175 180	after
E14	Temporal-Connection:T59 Arg:E15 Arg2:E5
A13	Temporal-Connection-Type-Value E14 after
T60	Eq-Comparison 207 215	received
E18	Eq-Comparison:T60 Temporal-Period:T61
T61	Eq-Temporal-Period 207 215	received
A14	Eq-Temporal-Period-Value T61 past
T62	Stability 216 222	stable
A15	Stability-Value T62 stable
T63	Eq-Unit 258 260	mg
T64	Eq-Temporal-Unit 261 264	day
A16	Eq-Temporal-Unit-Value T64 day
T65	Drug 268 278	prednisone
E16	Drug:T65 Name:T66 Dose:E31 Duration:E22
T66	Drug-Name 268 278	prednisone
T67	And 249 253	with
E20	And:T67 Arg:E11 Arg2:E16
T68	Eq-Comparison 283 300	at least 3 months
E22	Eq-Comparison:T68 Operator:T69 Value:T41 Temporal-Unit:T38
T69	Eq-Operator 283 291	at least
A17	Eq-Operator-Value T69 GTEQ
T70	Study 308 313	study
E24	Study:T70 Temporality:E26
T71	Eq-Comparison 314 319	start
E26	Eq-Comparison:T71 Temporal-Recency:T72
T72	Eq-Temporal-Recency 314 319	start
A18	Eq-Temporal-Recency-Value T72 first-time
T73	Temporal-Connection 301 307	before
E28	Temporal-Connection:T73 Arg:E22 Arg2:E24
A19	Temporal-Connection-Type-Value E28 before
T74	Observation 329 357	Karnofsky Performance Status
E35	Observation:T74 Name:T75
T75	Observation-Name 329 357	Karnofsky Performance Status
A20	Observation-Type-Value T75 clinical-score
T76	Observation 359 362	KPS
E36	Observation:T76 Name:T77 Eq-Comparison:E32
T77	Observation-Name 359 362	KPS
R4	Abbrev-Of Arg1:E36 Arg2:E35	
T78	Eq-Unit 370 371	%
T79	Observation 381 396	vitamin A level
E37	Observation:T79 Name:T80 Eq-Comparison:E38
T80	Observation-Name 381 396	vitamin A level
A21	Observation-Type-Value T80 lab
T81	Eq-Comparison 397 443	greater than or equal to lower limit of normal
E38	Eq-Comparison:T81 Operator:T34 Unit:T82
T82	Eq-Unit 422 443	lower limit of normal
A22	Eq-Unit-Value T82 ref-range-normal
T83	Eq-Comparison 473 492	previously received
E39	Eq-Comparison:T83 Temporal-Period:T84
T84	Eq-Temporal-Period 473 492	previously received
A23	Eq-Temporal-Period-Value T84 past
T85	Drug 493 502	inotersen
E40	Drug:T85 Name:T86 Temporality:E39
T86	Drug-Name 493 502	inotersen
T87	Drug 506 515	patisiran
E41	Drug:T87 Name:T88
T88	Drug-Name 506 515	patisiran
T89	Or 503 505	or
E42	Or:T89 Arg:E40 Arg2:E41
T90	Observation 548 567	liver function test
E43	Observation:T90 Name:T91 Polarity:T92 Severity:T93
T91	Observation-Name 548 567	liver function test
A24	Observation-Type-Value T91 lab
T92	Polarity 568 581	abnormalities
A25	Polarity-Value T92 abnormal
T93	Severity 536 547	significant
A26	Severity-Value T93 severe
T94	And 617 621	with
E44	And:T94 Arg:E1 Arg2:E13
T95	Observation 639 675	estimated glomerular filtration rate
E45	Observation:T95 Name:T96
T96	Observation-Name 639 675	estimated glomerular filtration rate
A27	Observation-Type-Value T96 lab
T97	Observation 677 681	eGFR
E46	Observation:T97 Name:T98 Eq-Comparison:E33
T98	Observation-Name 677 681	eGFR
A28	Observation-Type-Value T98 lab
R5	Abbrev-Of Arg1:E46 Arg2:E45	
T99	Eq-Unit 687 689	mL
T100	Eq-Temporal-Unit 690 693	min
A29	Eq-Temporal-Unit-Value T100 minute
T101	Eq-Unit 694 702	1.73 m^2
T102	Modifier 718 732	leptomeningeal
E47	Modifier:T102 Modifies:T26
T103	Condition 754 763	infection
E48	Condition:T103 Name:T104
T104	Condition-Name 754 763	infection
T105	And 764 768	with
E49	And:T105 Arg:E48 Arg2:E27
T106	Condition 827 830	HIV
E50	Condition:T106 Name:T107
T107	Condition-Name 827 830	HIV
T108	Or 794 796	or
E51	Or:T108 Arg:E29 Arg2:E17
R6	Abbrev-Of Arg1:E50 Arg2:E17	
T109	Eq-Comparison 950 958	received
E52	Eq-Comparison:T109 Temporal-Period:T115
T110	Condition 911 927	wheelchair bound
E53	Condition:T110 Name:T111
T111	Condition-Name 911 927	wheelchair bound
T112	Condition 931 940	bedridden
E54	Condition:T112 Name:T113
T113	Condition-Name 931 940	bedridden
T114	Or 928 930	or
E55	Or:T114 Arg:E53 Arg2:E54
T115	Eq-Temporal-Period 950 958	received
A30	Eq-Temporal-Period-Value T115 past
T116	Exception 977 987	other than
E56	Exception:T116 From:E19 Except:E21
T117	Assertion 1010 1017	Will be
E57	Assertion:T117 Asserted:E58
A31	Assertion-Type-Value E57 hypothetical
T118	Procedure 1033 1052	tetramer stabilizer
E58	Procedure:T118 Name:T119
T119	Procedure-Name 1033 1052	tetramer stabilizer
T120	Other 1027 1032	other
E59	Other:T120 Is-Other:E58
T121	Study 1064 1069	study
E60	Study:T121 
T122	Temporal-Connection 1053 1059	during
E61	Temporal-Connection:T122 Arg:E58 Arg2:E60
A32	Temporal-Connection-Type-Value E61 during
